Literature DB >> 24009227

Acquired copy number alterations of miRNA genes in acute myeloid leukemia are uncommon.

Giridharan Ramsingh1, Meagan A Jacoby, Jin Shao, Rigoberto E De Jesus Pizzaro, Dong Shen, Maria Trissal, Angela H Getz, Timothy J Ley, Matthew J Walter, Daniel C Link.   

Abstract

Altered microRNA (miRNA) expression is frequently observed in acute myelogenous leukemia (AML) and has been implicated in leukemic transformation. Whether somatic copy number alterations (CNAs) are a frequent cause of altered miRNA gene expression is largely unknown. Herein, we used comparative genomic hybridization with a custom high-resolution miRNA-centric array and/or whole-genome sequence data to identify somatic CNAs involving miRNA genes in 113 cases of AML, including 50 cases of de novo AML, 18 cases of relapsed AML, 15 cases of secondary AML following myelodysplastic syndrome, and 30 cases of therapy-related AML. We identified a total of 48 somatic miRNA gene-containing CNAs that were not identified by routine cytogenetics in 20 patients (18%). All these CNAs also included one or more protein coding genes. We identified a single case with a hemizygous deletion of MIR223, resulting in the complete loss of miR-223 expression. Three other cases of AML were identified with very low to absent miR-223 expression, an miRNA gene known to play a key role in myelopoiesis. However, in these cases, no somatic genetic alteration of MIR223 was identified, suggesting epigenetic silencing. These data show that somatic CNAs specifically targeting miRNA genes are uncommon in AML.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24009227      PMCID: PMC3795465          DOI: 10.1182/blood-2013-03-488007

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA.

Authors:  Ranhui Duan; Changhui Pak; Peng Jin
Journal:  Hum Mol Genet       Date:  2007-03-30       Impact factor: 6.150

3.  A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis.

Authors:  Francesco Fazi; Alessandro Rosa; Alessandro Fatica; Vania Gelmetti; Maria Laura De Marchis; Clara Nervi; Irene Bozzoni
Journal:  Cell       Date:  2005-12-02       Impact factor: 41.582

4.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Manuela Ferracin; Amelia Cimmino; Gianpiero Di Leva; Masayoshi Shimizu; Sylwia E Wojcik; Marilena V Iorio; Rosa Visone; Nurettin Ilfer Sever; Muller Fabbri; Rodolfo Iuliano; Tiziana Palumbo; Flavia Pichiorri; Claudia Roldo; Ramiro Garzon; Cinzia Sevignani; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

5.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

6.  Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.

Authors:  Francesco Fazi; Serena Racanicchi; Giuseppe Zardo; Linda M Starnes; Marco Mancini; Lorena Travaglini; Daniela Diverio; Emanuele Ammatuna; Giuseppe Cimino; Francesco Lo-Coco; Francesco Grignani; Clara Nervi
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

7.  Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

Authors:  M J Walter; D Shen; J Shao; L Ding; B S White; C Kandoth; C A Miller; B Niu; M D McLellan; N D Dees; R Fulton; K Elliot; S Heath; M Grillot; P Westervelt; D C Link; J F DiPersio; E Mardis; T J Ley; R K Wilson; T A Graubert
Journal:  Leukemia       Date:  2013-02-27       Impact factor: 11.528

8.  Regulation of progenitor cell proliferation and granulocyte function by microRNA-223.

Authors:  Jonathan B Johnnidis; Marian H Harris; Robert T Wheeler; Sandra Stehling-Sun; Michael H Lam; Oktay Kirak; Thijn R Brummelkamp; Mark D Fleming; Fernando D Camargo
Journal:  Nature       Date:  2008-02-17       Impact factor: 49.962

9.  MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia.

Authors:  Shuangli Mi; Jun Lu; Miao Sun; Zejuan Li; Hao Zhang; Mary Beth Neilly; Yungui Wang; Zhijian Qian; Jie Jin; Yanming Zhang; Stefan K Bohlander; Michelle M Le Beau; Richard A Larson; Todd R Golub; Janet D Rowley; Jianjun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-04       Impact factor: 11.205

10.  MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis.

Authors:  S Debernardi; S Skoulakis; G Molloy; T Chaplin; A Dixon-McIver; B D Young
Journal:  Leukemia       Date:  2007-03-01       Impact factor: 11.528

View more
  9 in total

1.  Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.

Authors:  Julian Wampfler; Elena A Federzoni; Bruce E Torbett; Martin F Fey; Mario P Tschan
Journal:  J Leukoc Biol       Date:  2015-05-19       Impact factor: 4.962

Review 2.  MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.

Authors:  Jared A Wallace; Ryan M O'Connell
Journal:  Blood       Date:  2017-07-27       Impact factor: 22.113

3.  MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.

Authors:  Bernhard Gentner; Nicole Pochert; Arefeh Rouhi; Francesco Boccalatte; Tiziana Plati; Tobias Berg; Su Ming Sun; Sarah M Mah; Milijana Mirkovic-Hösle; Jens Ruschmann; Andrew Muranyi; Simon Leierseder; Bob Argiropoulos; Daniel T Starczynowski; Aly Karsan; Michael Heuser; Donna Hogge; Fernando D Camargo; Stefan Engelhardt; Hartmut Döhner; Christian Buske; Mojca Jongen-Lavrencic; Luigi Naldini; R Keith Humphries; Florian Kuchenbauer
Journal:  Exp Hematol       Date:  2015-07-08       Impact factor: 3.084

4.  MicroRNA-223 regulates granulopoiesis but is not required for HSC maintenance in mice.

Authors:  Maria C Trissal; Ricardo A DeMoya; Amy P Schmidt; Daniel C Link
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 5.  miRNAs in acute myeloid leukemia.

Authors:  Qiong Liao; Bingping Wang; Xia Li; Guosheng Jiang
Journal:  Oncotarget       Date:  2017-01-10

6.  Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation.

Authors:  Hooi Ching Lim; Shamit Soneji; Róbert Pálmason; Stig Lenhoff; Thomas Laurell; Stefan Scheding
Journal:  Biomark Res       Date:  2021-01-19

Review 7.  The Role of cis- and trans-Acting RNA Regulatory Elements in Leukemia.

Authors:  Irina A Elcheva; Vladimir S Spiegelman
Journal:  Cancers (Basel)       Date:  2020-12-20       Impact factor: 6.639

8.  MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis.

Authors:  Maria C Trissal; Terrence N Wong; Juo-Chin Yao; Rahul Ramaswamy; Iris Kuo; Jack Baty; Yaping Sun; Gloria Jih; Nishi Parikh; Melissa M Berrien-Elliott; Todd A Fehniger; Timothy J Ley; Ivan Maillard; Pavan R Reddy; Daniel C Link
Journal:  Cancer Res       Date:  2018-05-03       Impact factor: 13.312

9.  The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia.

Authors:  M A Jacoby; R E De Jesus Pizarro; J Shao; D C Koboldt; R S Fulton; G Zhou; R K Wilson; M J Walter
Journal:  Leukemia       Date:  2013-12-05       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.